Insider Transactions in Q1 2021 at Ionis Pharmaceuticals Inc (IONS)
Insider Transaction List (Q1 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 01
2021
|
Brett P Monia Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
236
-0.47%
|
$12,744
$54.27 P/Share
|
|
Feb 26
2021
|
Brett P Monia Chief Executive Officer |
BUY
Other acquisition or disposition
|
Direct |
247
+0.49%
|
$10,868
$44.54 P/Share
|
|
Feb 26
2021
|
C Frank Bennett EVP, Chief Scientific Officer |
BUY
Other acquisition or disposition
|
Direct |
112
+0.26%
|
$4,928
$44.54 P/Share
|
|
Feb 26
2021
|
Onaiza Cadoret Manier EVP, Chf GL Pdt Str & Oper Ofc |
BUY
Other acquisition or disposition
|
Direct |
492
+50.0%
|
$21,648
$44.54 P/Share
|
|
Feb 26
2021
|
Richard S Geary EVP, Chief Development Officer |
BUY
Other acquisition or disposition
|
Direct |
414
+0.98%
|
$18,216
$44.54 P/Share
|
|
Feb 26
2021
|
Elizabeth L Hougen EVP, Finance & CFO |
BUY
Other acquisition or disposition
|
Direct |
116
+0.27%
|
$5,104
$44.54 P/Share
|
|
Feb 26
2021
|
Patrick R. O'Neil EVP CLO & General Counsel |
BUY
Other acquisition or disposition
|
Direct |
197
+0.73%
|
$8,668
$44.54 P/Share
|
|
Feb 26
2021
|
Eric Swayze EVP Research |
BUY
Other acquisition or disposition
|
Direct |
460
+3.91%
|
$20,240
$44.54 P/Share
|
|
Jan 28
2021
|
Brett P Monia Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,306
-2.54%
|
$78,360
$60.69 P/Share
|
|
Jan 28
2021
|
Brett P Monia Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,634
+4.87%
|
-
|
|
Jan 26
2021
|
Stanley T Crooke Exec Chairman of the Board |
SELL
Open market or private sale
|
Direct |
28,333
-93.34%
|
$1,784,979
$63.74 P/Share
|
|
Jan 25
2021
|
Patrick R. O'Neil EVP CLO & General Counsel |
SELL
Open market or private sale
|
Direct |
5,324
-16.73%
|
$335,412
$63.5 P/Share
|
|
Jan 22
2021
|
Stanley T Crooke Exec Chairman of the Board |
SELL
Open market or private sale
|
Indirect |
40,000
-7.49%
|
$2,440,000
$61.67 P/Share
|
|
Jan 21
2021
|
Stanley T Crooke Exec Chairman of the Board |
SELL
Open market or private sale
|
Indirect |
35,000
-3.12%
|
$2,135,000
$61.09 P/Share
|
|
Jan 15
2021
|
Eric Swayze EVP Research |
SELL
Payment of exercise price or tax liability
|
Direct |
3,216
-22.89%
|
$196,176
$61.28 P/Share
|
|
Jan 15
2021
|
Eric Swayze EVP Research |
BUY
Exercise of conversion of derivative security
|
Direct |
8,944
+38.9%
|
-
|
|
Jan 15
2021
|
Eugene Schneider EVP, Chf Clinical Develop Ofcr |
SELL
Payment of exercise price or tax liability
|
Direct |
2,718
-28.25%
|
$165,798
$61.28 P/Share
|
|
Jan 15
2021
|
Eugene Schneider EVP, Chf Clinical Develop Ofcr |
BUY
Exercise of conversion of derivative security
|
Direct |
7,503
+43.82%
|
-
|
|
Jan 15
2021
|
B Lynne Parshall Director |
SELL
Payment of exercise price or tax liability
|
Direct |
2,741
-4.02%
|
$167,201
$61.28 P/Share
|
|
Jan 15
2021
|
B Lynne Parshall Director |
BUY
Exercise of conversion of derivative security
|
Direct |
10,655
+13.53%
|
-
|
|
Jan 15
2021
|
Patrick R. O'Neil EVP CLO & General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
5,856
-15.54%
|
$357,216
$61.28 P/Share
|
|
Jan 15
2021
|
Patrick R. O'Neil EVP CLO & General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
16,504
+30.46%
|
-
|
|
Jan 15
2021
|
Brett P Monia Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
14,927
-23.43%
|
$910,547
$61.28 P/Share
|
|
Jan 15
2021
|
Brett P Monia Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
34,823
+35.34%
|
-
|
|
Jan 15
2021
|
Elizabeth L Hougen EVP, Finance & CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
6,175
-12.44%
|
$376,675
$61.28 P/Share
|
|
Jan 15
2021
|
Elizabeth L Hougen EVP, Finance & CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
17,151
+25.68%
|
-
|
|
Jan 15
2021
|
Richard S Geary EVP, Chief Development Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
6,398
-13.36%
|
$390,278
$61.28 P/Share
|
|
Jan 15
2021
|
Richard S Geary EVP, Chief Development Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
17,598
+26.87%
|
-
|
|
Jan 15
2021
|
C Frank Bennett EVP, Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
5,488
-11.43%
|
$334,768
$61.28 P/Share
|
|
Jan 15
2021
|
C Frank Bennett EVP, Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
15,520
+24.43%
|
-
|
|
Jan 15
2021
|
Stanley T Crooke Exec Chairman of the Board |
SELL
Payment of exercise price or tax liability
|
Indirect |
1,434
-31.55%
|
$87,474
$61.28 P/Share
|
|
Jan 15
2021
|
Stanley T Crooke Exec Chairman of the Board |
BUY
Exercise of conversion of derivative security
|
Indirect |
4,371
+49.02%
|
-
|
|
Jan 15
2021
|
Stanley T Crooke Exec Chairman of the Board |
SELL
Payment of exercise price or tax liability
|
Direct |
18,924
-38.4%
|
$1,154,364
$61.28 P/Share
|
|
Jan 15
2021
|
Stanley T Crooke Exec Chairman of the Board |
BUY
Exercise of conversion of derivative security
|
Direct |
47,257
+48.95%
|
-
|
|
Jan 13
2021
|
Richard S Geary EVP, Chief Development Officer |
SELL
Open market or private sale
|
Direct |
141
-0.46%
|
$8,319
$59.5 P/Share
|
|
Jan 05
2021
|
Eric Swayze EVP Research |
SELL
Open market or private sale
|
Direct |
195
-3.68%
|
$10,725
$55.99 P/Share
|